Cargando…

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections

BACKGROUND: We conducted this study to describe the clinical characteristics, microbiology, and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug-resistant Gram-negative (MDR-GN) infections. METHODS: This is a multicenter, retrospective cohort study conducted at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorgensen, Sarah C J, Trinh, Trang D, Zasowski, Evan J, Lagnf, Abdalhamid M, Bhatia, Sahil, Melvin, Sarah M, Steed, Molly E, Simon, Samuel P, Estrada, Sandra J, Morrisette, Taylor, Claeys, Kimberly C, Rosenberg, Joshua R, Davis, Susan L, Rybak, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934163/ https://www.ncbi.nlm.nih.gov/pubmed/31890725 http://dx.doi.org/10.1093/ofid/ofz522

Ejemplares similares

2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah, et al.
Publicado: (2018)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane–Tazobactam: Impact of Delayed Initiation
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1061. Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1073. Predictors of Vancomycin Switch or Escalation in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Lagnf, Abdalhamid M, et al.
Publicado: (2018)

Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis
por: Claeys, Kimberly C., et al.
Publicado: (2017)

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2019)

Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study
por: Alosaimy, Sara, et al.
Publicado: (2021)

Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Zasowski, Evan J, et al.
Publicado: (2021)

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis
por: Alosaimy, Sara, et al.
Publicado: (2020)

Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Trinh, Trang D, et al.
Publicado: (2017)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections
por: Trinh, Trang D., et al.
Publicado: (2018)

Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2019)

Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2020)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil
por: Carvalho, Thaisa Noceti, et al.
Publicado: (2023)

Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
por: DUMLU, Rıdvan, et al.
Publicado: (2022)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
por: Li, Dan, et al.
Publicado: (2021)

2250. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting
por: Claeys, Kimberly C., et al.
Publicado: (2018)

Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study
por: Rybak, Michael J., et al.
Publicado: (2018)

1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Alosaimy, Sara, et al.
Publicado: (2019)

Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections
por: Jorgensen, Sarah C. J., et al.
Publicado: (2019)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2023)

1422. Comparative Monte-Carlo Analysis of Aztreonam-Avibactam vs. Ceftazidime–Avibactam Against Carbapenem-Resistant Gram-Negative Pathogens
por: Smith, Aaron, et al.
Publicado: (2018)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae Carbapenemase–Producing Klebsiella pneumoniae Infections: A Retrospective, Observational, 2-Center Clinical Study
por: Oliva, Alessandra, et al.
Publicado: (2023)

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
por: Gonzalez, Mark D., et al.
Publicado: (2017)

1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
por: Criscuolo, Marianna, et al.
Publicado: (2020)

Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection
por: Xiao, Shuang, et al.
Publicado: (2023)

Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU
por: Yu, Jiaxin, et al.
Publicado: (2023)

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points
por: Torres, Antoni, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mu4ujv5856lp03am7f56vq4a2s